🏛️ Verified NIH Record • Updated 2025-09-02
A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer (NCT01770418)
🔵 Active, Not Recruiting Phase1 / Phase2 📋 Clinical Research Protocol Sponsor: Proton Collaborative Group
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this research study is to compare the effects (good and bad) on subjects and their cancer using standard chemotherapy in combination with hypofractionated proton radiation therapy. Hypofractionation is a technique that delivers higher daily doses of radiation over a shorter period of time.
Who can join: Review the eligibility criteria below.
Location: University of Florida Proton Therapy Institute — Jacksonville, Florida
Age range: 18 Years
🧪 Interventions in This Study
- Radiation with Concurrent Chemotherapy (RADIATION)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (6 Sites)
- University of Florida Proton Therapy Institute — Jacksonville, Florida
- Northwestern Medicine Chicago Proton Center — Warrenville, Illinois
- Maryland Proton Treatment Center — Baltimore, Maryland
- Princeton ProCure Management LLC — Somerset, New Jersey
- Oklahoma Proton Center — Oklahoma City, Oklahoma
- Hampton University Proton Therapy Institute — Hampton, Virginia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lung Neoplasms
- Advancing Precision Lung Cancer Surveillance and Outcomes in Diverse Populations — Gainesville, Florida
- Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) — Mobile, Alabama
- Circulating Tumor Cells (CTC) in Lung Cancer — Indianapolis, Indiana
- Specimen Banking From Patients With Lung Cancer — Aurora, Colorado
- TELEhealth Shared Decision-making COaching for Lung Cancer Screening in Primary Care (TELESCOPE) for Hispanics — New Brunswick, New Jersey
Explore by condition: All Lung Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.